Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential or males~* 18 to 45 years of age~* Judged by the Principal Investigator to be healthy on the basis of medical history and a pre-study physical examination including 12-lead electrocardiogram (ECG), 24-hour Holter ECG, vital signs and blood and urine laboratory assessments.~Exclusion Criteria:~* Females of childbearing potential~* Clinically significant disease~* Clinically significant abnormal laboratory, ECG, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SOBI002 (Type: EXPERIMENTAL): Single and repeated administration of different doses of test product
- placebo (Type: PLACEBO_COMPARATOR): Single and repeated administration of placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).